TWI925837B - 包含干擾素基因之刺激因子(sting)的促效劑之支架和抗體-藥物共軛體及製造彼等之方法、包含該抗體-藥物共軛體之醫藥組成物、及該抗體-藥物共軛體和醫藥組成物之用途 - Google Patents
包含干擾素基因之刺激因子(sting)的促效劑之支架和抗體-藥物共軛體及製造彼等之方法、包含該抗體-藥物共軛體之醫藥組成物、及該抗體-藥物共軛體和醫藥組成物之用途Info
- Publication number
- TWI925837B TWI925837B TW110112338A TW110112338A TWI925837B TW I925837 B TWI925837 B TW I925837B TW 110112338 A TW110112338 A TW 110112338A TW 110112338 A TW110112338 A TW 110112338A TW I925837 B TWI925837 B TW I925837B
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- seq
- amino acid
- cancer
- acid sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
- A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004108P | 2020-04-02 | 2020-04-02 | |
| US63/004,108 | 2020-04-02 | ||
| US202063040755P | 2020-06-18 | 2020-06-18 | |
| US63/040,755 | 2020-06-18 | ||
| US202063111820P | 2020-11-10 | 2020-11-10 | |
| US63/111,820 | 2020-11-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202203977A TW202203977A (zh) | 2022-02-01 |
| TWI925837B true TWI925837B (zh) | 2026-05-21 |
Family
ID=75660370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110112338A TWI925837B (zh) | 2020-04-02 | 2021-04-06 | 包含干擾素基因之刺激因子(sting)的促效劑之支架和抗體-藥物共軛體及製造彼等之方法、包含該抗體-藥物共軛體之醫藥組成物、及該抗體-藥物共軛體和醫藥組成物之用途 |
Country Status (17)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112300227B (zh) | 2019-07-25 | 2023-11-28 | 江西济民可信集团有限公司 | 杂环酰胺类化合物及其制备方法和应用 |
| KR20220056176A (ko) | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
| CN116196435B (zh) * | 2020-04-02 | 2025-12-02 | 梅尔莎纳医疗公司 | 包含sting激动剂的抗体药物缀合物 |
| WO2022147532A1 (en) | 2021-01-04 | 2022-07-07 | Mersana Therapeutics, Inc. | B7h4-targeted antibody-drug conjugates and methods of use thereof |
| US20250057967A2 (en) * | 2021-06-25 | 2025-02-20 | Bolt Biotherapeutics, Inc. | Bis-benzimidazole sting agonist immunoconjugates, and uses thereof |
| WO2023100829A1 (ja) | 2021-11-30 | 2023-06-08 | 第一三共株式会社 | プロテアーゼ分解性マスク抗体 |
| US20250108123A1 (en) * | 2021-12-17 | 2025-04-03 | Jacobio Pharmaceuticals Co., Ltd. | Compound-linker constructs comprising novel compounds useful as sting agonists and uses thereof |
| WO2023136589A1 (en) * | 2022-01-11 | 2023-07-20 | Bisichem Co., Ltd. | Fused heteroaryl hydroxamates as sting agonists |
| AU2023218678A1 (en) | 2022-02-09 | 2024-08-01 | Daiichi Sankyo Company, Limited | Environmentally responsive masked antibody and use thereof |
| MX2024010916A (es) * | 2022-03-07 | 2024-09-17 | Mersana Therapeutics Inc | Conjugados anticuerpo-farmaco que comprenden agonistas de sting, combinaciones y metodos de uso. |
| EP4518905A1 (en) * | 2022-05-06 | 2025-03-12 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
| KR20250054799A (ko) | 2022-08-29 | 2025-04-23 | 다이이찌 산쿄 가부시키가이샤 | 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트 |
| IL320284A (en) * | 2022-10-18 | 2025-06-01 | Tubulis Gmbh | Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof |
| KR20250089528A (ko) * | 2022-10-18 | 2025-06-18 | 투불리스 게엠베하 | 신규한 napi2b 항체를 함유하는 신규한 항체 약물 접합체, 치료 방법 및 이의 용도 |
| WO2024137619A1 (en) * | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| WO2024186626A1 (en) * | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| WO2024192017A1 (en) * | 2023-03-13 | 2024-09-19 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists, combinations and methods of use |
| TW202545568A (zh) | 2024-01-29 | 2025-12-01 | 日商第一三共股份有限公司 | 抗her2抗體-藥物結合物與其他劑之組合 |
| WO2025233682A1 (en) * | 2024-05-08 | 2025-11-13 | Ligachem Biosciences Inc. | Antibody drug conjugates comprising sting agonists and uses thereof |
| TW202615010A (zh) * | 2024-06-24 | 2026-04-16 | 大陸商北京加科思新藥研發有限公司 | 藥物連接子、其偶聯物及其用途 |
| WO2026078593A1 (en) | 2024-10-08 | 2026-04-16 | Sun Pharma Advanced Research Company Limited | Sting agonists and antibody drug conjugates thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018098269A2 (en) * | 2016-11-23 | 2018-05-31 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| WO2018160538A1 (en) * | 2017-02-28 | 2018-09-07 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
| WO2018200812A1 (en) * | 2017-04-28 | 2018-11-01 | Novartis Ag | Antibody conjugates comprising sting agonist |
| WO2019069275A1 (en) * | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | STING AGONIST ADMINISTRATION METHODS |
| TW202317202A (zh) * | 2020-04-02 | 2023-05-01 | 美商梅爾莎納醫療公司 | 包含干擾素基因之刺激因子(sting)的促效劑之抗體-藥物共軛體 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080070981A1 (en) | 2000-02-23 | 2008-03-20 | Henryk Borowy-Borowski | Water-soluble compositions of bioactive lipophilic compounds |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| AU2002234755A1 (en) | 2001-02-26 | 2002-09-12 | Pharma Pacific Pty Ltd | Interferon-alpha induced gene |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| US8367065B2 (en) | 2006-09-15 | 2013-02-05 | Enzon Pharmaceuticals, Inc. | Targeted polymeric prodrugs containing multifunctional linkers |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| BRPI0812970A2 (pt) | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
| EP2250201B1 (en) | 2008-01-29 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| EA201590622A1 (ru) | 2012-10-16 | 2015-10-30 | Эндосайт, Инк. | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения |
| SG11201502796RA (en) | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| PT3057585T (pt) | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
| MA39909B1 (fr) * | 2014-04-25 | 2019-05-31 | Pf Medicament | Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer |
| EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
| DK3233882T3 (da) | 2014-12-16 | 2020-01-27 | Kayla Therapeutics | Fluorinerede cykliske dinukleotider til cytokininduktion |
| EP3233191A1 (en) | 2014-12-16 | 2017-10-25 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN108137641B (zh) | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
| KR20180066241A (ko) | 2015-10-28 | 2018-06-18 | 아두로 바이오테크, 인코포레이티드 | “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법 |
| JP6411676B2 (ja) | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Stingの調節因子としての環状プリンジヌクレオチド |
| DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| US20170158772A1 (en) * | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
| BR112018068461A2 (pt) | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| US10225009B2 (en) | 2016-07-01 | 2019-03-05 | Adtran, Inc. | Broadband access devices having a radio link |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| JP6636673B2 (ja) | 2016-10-04 | 2020-01-29 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | STINGアゴニストとしてのベンゾ[b]チオフェン化合物 |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| WO2018227023A1 (en) | 2017-06-07 | 2018-12-13 | Silverback Therapeutics, Inc. | Antibody construct conjugates |
| AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
| MA49772A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
| EP3685166A2 (en) | 2017-09-20 | 2020-07-29 | Mersana Therapeutics, Inc. | Compositions and methods for predicting response to napi2b-targeted therapy |
| US11377440B2 (en) | 2017-10-05 | 2022-07-05 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) |
| AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| CA3247730A1 (en) | 2017-11-07 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| CN110016021B (zh) | 2018-01-08 | 2021-05-07 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN110016025B (zh) | 2018-01-08 | 2021-08-06 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| US10793557B2 (en) | 2018-04-03 | 2020-10-06 | Merck Sharp & Dohme Corp. | Sting agonist compounds |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| EP3802534B1 (en) | 2018-05-25 | 2022-07-13 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
| US20210353652A1 (en) | 2018-06-04 | 2021-11-18 | Trustees Of Tufts College | Tumor microenvironment-activated drug-binder conjugates, and uses related thereto |
| WO2019243825A1 (en) | 2018-06-21 | 2019-12-26 | Curadev Pharma Limited | Small molecule modulators of human sting, conjugates and therapeutic applications |
| CN112351778B (zh) | 2018-06-28 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 稠合三环杂环类化合物及其治疗用途 |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| AU2019326633B2 (en) | 2018-08-24 | 2022-09-08 | Adlai Nortye Biopharma Co., Ltd. | High activity sting protein agonist |
| CA3110474C (en) | 2018-08-29 | 2024-04-23 | Adlai Nortye Biopharma Co., Ltd. | Highly active sting protein agonist compound |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| CN110963997A (zh) | 2018-09-28 | 2020-04-07 | 四川科伦博泰生物医药股份有限公司 | 杂环酰胺类化合物、包含其的药物组合物及其制备方法和用途 |
| WO2020115676A1 (en) | 2018-12-06 | 2020-06-11 | Glaxosmithkline Intellectual Property Development Limited | Novel pharmaceutical formulation |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| WO2020132549A1 (en) | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting heterocycle agonists and uses thereof |
| WO2020132566A1 (en) | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting pyrazole agonists and uses thereof |
| CN111393405B (zh) | 2019-01-02 | 2022-11-25 | 中国科学院上海药物研究所 | 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用 |
| CN111393404B (zh) | 2019-01-02 | 2023-02-17 | 中国科学院上海药物研究所 | 一类苯并噻吩类化合物及其药物组合物及应用 |
| WO2020146237A1 (en) | 2019-01-07 | 2020-07-16 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| CN111471056B (zh) | 2019-01-23 | 2021-07-02 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
| KR102702618B1 (ko) | 2019-01-31 | 2024-09-06 | 히트젠 주식회사 | 면역조절제 |
| WO2020181050A1 (en) | 2019-03-05 | 2020-09-10 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| KR20210146370A (ko) | 2019-03-28 | 2021-12-03 | 루핀 리미티드 | Sting 효능제로서의 매크로사이클릭 화합물 |
| TW202104214A (zh) | 2019-04-05 | 2021-02-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| JP2022529183A (ja) | 2019-04-17 | 2022-06-17 | アヴィディア テクノロジーズ, インコーポレイテッド | リガンド提示および/または薬物送達のためのスターポリマーを製造する組成物および方法 |
| CN111848573B (zh) | 2019-04-30 | 2023-04-07 | 四川科伦博泰生物医药股份有限公司 | 苯并噻吩酰胺类化合物及其制备方法和用途 |
| JP7531508B2 (ja) | 2019-04-30 | 2024-08-09 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | ベンゾチオフェン化合物、その調製方法およびその使用 |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| WO2021000770A1 (zh) | 2019-07-02 | 2021-01-07 | 凯复制药有限公司 | 可增强免疫活性的杂环化合物、其制备方法及其在医药上的应用 |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| DK4004002T3 (da) | 2019-07-22 | 2024-09-30 | Lupin Ltd | Makrocykliske forbindelser som sting-agonister samt fremgangsmåder og anvendelser dermed |
| CN112300227B (zh) | 2019-07-25 | 2023-11-28 | 江西济民可信集团有限公司 | 杂环酰胺类化合物及其制备方法和应用 |
| KR20220056176A (ko) * | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
| US20230074558A1 (en) | 2019-12-06 | 2023-03-09 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
| CN113248475B (zh) | 2020-02-11 | 2023-03-17 | 中国科学院上海药物研究所 | 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途 |
| WO2022147532A1 (en) | 2021-01-04 | 2022-07-07 | Mersana Therapeutics, Inc. | B7h4-targeted antibody-drug conjugates and methods of use thereof |
| CN112898286A (zh) | 2021-01-28 | 2021-06-04 | 中国药科大学 | 苯并噻吩类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途 |
| MX2024010916A (es) | 2022-03-07 | 2024-09-17 | Mersana Therapeutics Inc | Conjugados anticuerpo-farmaco que comprenden agonistas de sting, combinaciones y metodos de uso. |
-
2021
- 2021-04-02 CN CN202310035173.6A patent/CN116196435B/zh active Active
- 2021-04-02 MY MYPI2022005482A patent/MY210304A/en unknown
- 2021-04-02 BR BR122022020762-6A patent/BR122022020762A2/pt unknown
- 2021-04-02 KR KR1020227043239A patent/KR20230004896A/ko active Pending
- 2021-04-02 US US17/221,341 patent/US20220378749A1/en not_active Abandoned
- 2021-04-02 AU AU2021248635A patent/AU2021248635B2/en active Active
- 2021-04-02 JP JP2022560199A patent/JP7871194B2/ja active Active
- 2021-04-02 IL IL296901A patent/IL296901A/en unknown
- 2021-04-02 MX MX2022012304A patent/MX2022012304A/es unknown
- 2021-04-02 WO PCT/US2021/025556 patent/WO2021202984A1/en not_active Ceased
- 2021-04-02 BR BR112022019919A patent/BR112022019919A2/pt unknown
- 2021-04-02 IL IL297859A patent/IL297859A/en unknown
- 2021-04-02 PH PH1/2022/552639A patent/PH12022552639A1/en unknown
- 2021-04-02 KR KR1020227037526A patent/KR20230005189A/ko active Pending
- 2021-04-02 CN CN202180039592.6A patent/CN115768485A/zh active Pending
- 2021-04-02 EP EP21721315.6A patent/EP4126065A1/en active Pending
- 2021-04-02 EP EP22215179.7A patent/EP4218826A3/en active Pending
- 2021-04-02 CA CA3174297A patent/CA3174297A1/en active Pending
- 2021-04-06 TW TW110112338A patent/TWI925837B/zh active
-
2022
- 2022-09-30 MX MX2022014230A patent/MX2022014230A/es unknown
- 2022-10-03 CL CL2022002711A patent/CL2022002711A1/es unknown
- 2022-10-12 AR ARP220102777A patent/AR127344A2/es unknown
- 2022-10-14 CL CL2022002837A patent/CL2022002837A1/es unknown
- 2022-10-27 AU AU2022259796A patent/AU2022259796B2/en active Active
- 2022-10-31 CO CONC2022/0015650A patent/CO2022015650A2/es unknown
- 2022-12-19 US US18/068,476 patent/US12440576B2/en active Active
- 2022-12-20 US US18/068,936 patent/US12156870B2/en active Active
- 2022-12-27 JP JP2022209755A patent/JP7777065B2/ja active Active
-
2024
- 2024-12-12 CL CL2024003823A patent/CL2024003823A1/es unknown
-
2025
- 2025-06-03 US US19/226,937 patent/US20250352662A1/en active Pending
-
2026
- 2026-02-17 JP JP2026023302A patent/JP2026086770A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018098269A2 (en) * | 2016-11-23 | 2018-05-31 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| WO2018160538A1 (en) * | 2017-02-28 | 2018-09-07 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
| WO2018200812A1 (en) * | 2017-04-28 | 2018-11-01 | Novartis Ag | Antibody conjugates comprising sting agonist |
| WO2019069275A1 (en) * | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | STING AGONIST ADMINISTRATION METHODS |
| TW202317202A (zh) * | 2020-04-02 | 2023-05-01 | 美商梅爾莎納醫療公司 | 包含干擾素基因之刺激因子(sting)的促效劑之抗體-藥物共軛體 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4347601A4 (en) | CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE | |
| EP4223785A4 (en) | Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition | |
| WO2015151079A3 (en) | Auristatin analogues and their conjugates with cell-binding molecules | |
| BR112015023391A8 (pt) | formulações de conjugados anticorpo-droga anti-egfr | |
| AU2022205057A9 (en) | B7h4-targeted antibody-drug conjugates and methods of use thereof | |
| EP4053155A4 (en) | KERATIN BD-4, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| EP4364802A3 (en) | Compositions comprising methylphenidate-prodrugs, processes of making and using the same | |
| EP4053154A4 (en) | KERATIN BD-10, METHOD FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITION THEREOF, AND ITS USE | |
| EP4223759A4 (en) | PYRAZOLOPYRIDAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING IT AND ITS USE | |
| WO2024130161A3 (en) | Novel camptothecin derivatives and conjugates thereof | |
| AU2024207684A1 (en) | Linkers, drug linkers and conjugates thereof and methods of using the same | |
| IL321863A (en) | Linkers, drug linkers and conjugates thereof and methods of using them | |
| EP4297723A4 (en) | MICRONEEDLE COMPOSITIONS AND METHODS OF RELEASE THEREOF | |
| EP4100005A4 (en) | ADAMTS INHIBITORS, METHODS OF MANUFACTURE AND MEDICAL USES THEREOF | |
| AU2023473631A1 (en) | Solid state forms, pharmaceutical compositions, preparation methods and use thereof | |
| CA3266804A1 (en) | PHARMACEUTICAL COMPOSITION AND ITS USE | |
| EP4364735A4 (en) | PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| AU2021360636A9 (en) | Triheterocyclic derivative, and pharmaceutical composition and application thereof | |
| CA3282892A1 (en) | Antibody-drug conjugates, pharmaceutical compositions and uses thereof | |
| HK40096436A (en) | Pharmaceutical composition comprising chloroquine and uses thereof | |
| HK40114800A (en) | Antibody-drug conjugate, pharmaceutical composition thereof and use thereof | |
| HK40111902A (en) | Camptothecin analogues, conjugates and methods of use | |
| CA3276571A1 (en) | Auristatin linker-payloads, pharmaceutical compositions, and uses thereof | |
| HK40128680A (en) | Auristatin linker-payloads, pharmaceutical compositions, and uses thereof | |
| HK40111269A (en) | Linkers, drug linkers and conjugates thereof and methods of using the same |